Email This Article
Headlines & Perspectives
Biotech Stock Mailbag: Chelsea Therapeutics
By
Adam Feuerstein
07/10/09 - 08:00 AM EDT
Readers weigh in on Chelsea's rheumatoid arthritis duo, Generex's diabetes spray, AMAG's stock dip, and Anadys' prospects.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,341.82 | 1,099.32 | 2,185.42 | 35.03 |
Oil *
72.47
|
|
DOWN
99.30
|
DOWN
9.86
|
DOWN
21.49
|
DOWN
0.93
|
10 Yr
3.50%
SPDR Gold
109.01
|
|
-0.95%
|
-0.89%
|
-0.97%
|
-2.59%
|
Data delayed 20 minutes |
Connect with TheStreet